Bloodstream Infection after Reduced-Intensity Umbilical Cord Blood Transplantation Versus Other Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4981-4981
Author(s):  
Shinsuke Takagi ◽  
Kazuya Ishiwata ◽  
Masanori Tsuji ◽  
Hisashi Yamamoto ◽  
Daisuke Kato ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cord Blood ◽  
Hematopoietic Stem Cell ◽  
Cord Blood Transplantation ◽  
Hematopoietic Stem ◽  
Blood Transplantation ◽  
Reduced Intensity

Abstract Blood stream infection (BSI) is a major cause of transplant-related mortality (TRM) following allogeneic hematopoietic stem cell transplantation, and to overcome it, reduced-intensity preparative regimens were developed in recent years. However, little information has been reported on BSI after reduced-intensity cord blood transplantation (RI-CBT). To clarify the characteristics of BSI after RI-CBT, we compared the incidence of microbiologically documented BSI before day 100 between RI-CBT and reduced-intensity non-cord blood allogeneic hematopoietic stem cell transplant (RI-non-CBT) recipients in Toranomon hospital, Japan. RI-non-CBT group includes related bone marrow (rBM), related peripheral blood stem cell (rPBSC) and unrelated bone marrow (uBM) transplantation. We retrospectively reviewed the first events of BSI in 211 consecutive adult patients between Jan 2004 and July 2006. One hundred and fifteen patients received RI-CBT and 96 patients received RI-non-CBT (4 from rBM, 34 from rPBSC and 58 from uBM). The median ages of patients in both groups were 55 years. All of the preparative regimens were fludarabine-based and prophylaxis against GVHD was tacrolimus alone in most of the RI-CBT recipients and combination of calcinurin inhibitor and short-term methotrexate in most of the RI-non-CBT recipients. The median time to achieve neutrophil engraftment was delayed in RI-CBT group (day 20 vs. day15). The cumulative incidence of engraftment at day 60 was 73.0% in RI-CBT group versus 90.6% in RI-non-CBT group. The cumulative incidence of BSI was 39.3% at day 100 and RI-CBT group tended to have more BSI compared to RI-non-CBT group (46.1% vs. 31.3%, p=0.0122), particularly at the early points after transplantation. Median day of positive culture for bacteremia was earlier (day 9 vs. day 14) in RI-CBT group. In spite of reduced-intensity preparative regimen, RI-CBT in adults is associated with higher rates of BSI at early time points after transplantation.

Reduced-Intensity Regimens in Allogeneic Hematopoietic Stem Cell Transplantation for Hemoglobinopathies

Hematology ◽  
2006 ◽  
Vol 2006 (1) ◽  
pp. 398-401 ◽  
Author(s):  
Franco Locatelli
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Cord Blood Transplantation ◽  
Hematopoietic Stem ◽  
Late Morbidity ◽  
Reduced Intensity

Abstract The only well-established curative therapy for patients with hemoglobinopathies is allogeneic hematopoietic stem cell transplantation (HSCT), which, in the last 20 years, has been mainly performed from an HLA-matched, related donor, using bone marrow as source of hematopoietic progenitors. More recent studies indicate that HSCT from unrelated donors may offer results comparable to those obtained with HLA-identical family donors, provided that stringent criteria of compatibility are employed for selecting the donor. Cord blood transplantation was also suggested to be an equally effective, but safer, procedure than bone marrow transplantation, due to the lower incidence and severity of both acute and chronic graft-versus-host disease. In view of the early, as well as late, morbidity and mortality associated with conventional myeloablative transplantation in patients with hemoglobinopathies, it is not surprising that great interest and relevant expectations for patients with hemoglobinopathies have been raised by the introduction in the clinical practice of reduced-intensity preparative regimens. However, few reports have demonstrated the feasibility of using reduced-intensity preparative regimens for successfully treating these patients and many treatment failures, mainly due to the lack of sustained donor engraftment, have been reported. Despite these limitations, some of the concepts obtained from the use of reduced intensity regimens, such as the substitution of fludarabine for cyclophosphamide, may be important to further improve the outcome of patients with hemoglobinopathies, especially of those with poor prognostic characteristics, given HSCT.

Three Hundred and Fifty Cases of Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Study in Korea.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5139-5139
Author(s):  
Young-Shil Park ◽  
Pil-Sang Jang ◽  
Sangrhim Choi ◽  
Nak-Gyun Chung ◽  
Bin Cho ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Cord Blood Transplantation ◽  
Hematopoietic Stem ◽  
Korean Children ◽  
Matched Sibling

Abstract Background: Hematopoietic stem cell transplantation (HST) was first introduced to Korean children in 1983. Since then HST has been a curative method for pediatric malignant or non-malignant hematologic disorders and the number of children receiving HST’s has been increasing steadily. Method: We analyzed three hundred and fifty cases of pediatric allogeneic hematopoietic stem cell transplantation between Nov. 1983 and Dec. 2003 in the Catholic Hematopoietic Stem Cell Transplantation Center of Korea. Results: HLA-matched sibling bone marrow transplantations were performed in 206 cases (103 males, 103 females, median age 12 years) with median follow-up of 73 months. The 5-year event-free survival (EFS) of ALL and AML was 70.5 % and 67.22 %, respectively. The 5-year EFS of severe aplastic anemia was 90.9 %. The 5-year EFS of CML/MDS and rare hematologic diseases was 65.5 % and 90.0 %, respectively. Eighty-one children (56 males, 25 females, median age 9 years) underwent unrelated bone marrow transplantation (UBMT), 42 (27 males, 15 females, median age 5 years) cord blood transplantation (CBT) and 21 (14 males, 7 females, median age 8 years) familial haploidentical HST (FHT). Three-year EFS of UBMT, CBT and FHT was 55.6 %, 48.0 % and 38.0 %, respectively. Conclusion: HLA-matched sibling allogeneic BMT showed better survival in children with hematopoietic stem cell disorders. Recently, transplants using alternative stem cell sources are increasing due to the lack of suitable sibling donors and continued efforts for reducing transplant-related complications are warranted for improved survival.

Sign in / Sign up

Export Citation Format

Share Document